Atossa Genetics, Inc.

Atossa Genetics, Inc.


On July 20, 2018, the Washington District Court approved a settlement of the case for $3.5 million in cash.

A copy of the judgment approving the settlement can be downloaded from the right sidebar.


We are investigating possible violations of federal securities laws by officers and directors of Atossa Genetics, Inc. (Atossa) (NASDAQ: ATOS).

On October 4, 2013, Atossa announced a voluntary recall to remove its ForeCYTE Breast Health Test and the Mammary Aspiration Specimen Cytology Test (MASCT) device from the market. The recall was initiated to address concerns raised by the U.S. Food and Drug Administration (FDA) in a warning letter received by Atossa in February 2013 about (1) the current instructions for use (IFU); (2) certain promotional claims used to market these devices; and (3) the need for FDA clearance for certain changes made to the Nipple Aspirate Fluid (NAF) specimen collection process identified in the current IFU.

Upon the above news, ATOS shares have declined over 45% in trading on October 7, 2013.

Persons with relevant information, and ATOS shareholders with questions about this investigation, are invited to contact the attorney below, or our Firm by calling 866.833.6245.


J. Elazar Fruchter